[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100495393":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":27,"locations":32,"responsibleParty":48,"collaborators":22,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":22,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":22,"enrollmentInfo":59,"targetDuration":22,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":22,"overallStatus":35,"whyStopped":22,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Vestre Viken Hospital Trust","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"Primary breast cancer","Patients diagnosed with new breast cancer determined to have \"high risk\" disease by a multidisciplinary team.",[12],"Other: 18F-FDG PET\u002FCT",{"label":14,"type":6,"description":15,"interventionNames":16},"Recurrent breast cancer","Patients with suspected or proven locoregional recurrent breast cancer.",[12],[18],{"type":6,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"18F-FDG PET\u002FCT","Included breast cancer patients will undergo a 18F-FDG PET\u002FCT scan in addition to conventional imaging with CT and bone scintigraphy.",[9,14],null,[24],{"name":25,"affiliation":5,"role":26},"Harald Grut, MD, PHD","PRINCIPAL_INVESTIGATOR",[28],{"name":25,"role":29,"phone":30,"phoneExt":22,"email":31},"CONTACT","004797108503","harald.grut@gmail.com",[33],{"facility":34,"status":35,"city":36,"state":22,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Drammen Hospital - Vestre Viken HF","RECRUITING","Drammen","N-3004","Norway","NO",{"type":41,"coordinates":42},"Point",[43,44],10.20449,59.74389,{"lat":44,"lon":43},[47],{"name":25,"role":29,"phone":22,"phoneExt":22,"email":22},{"type":49,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100495393","18f-fdg-petct-imaging-for-breast-cancer-100495393",false,"NCT05730608","18F-FDG PET\u002FCT Imaging for Breast Cancer","Improving Breast Cancer Staging With 18F-FDG PET\u002FCT Imaging (The IMBRECAS PET Study)","Inclusion Criteria:\n\n* Patients with high risk primary or recurrent breast cancer\n* Non pregnant women \\> 18 years\n* Not receiving active treatment of other cancer types.\n* Eastern Cooperative Oncology Group (ECOG) status 0-2.\n\nExclusion Criteria:\n\n* Pregnant woman\n* Males\n* Age under 18\n* Patients receiving active treatment for other cancers\n* Poor general conditipon (ECOG 3 or higher)","FEMALE","18 Years",{"count":60,"type":61},300,"ESTIMATED","INTERVENTIONAL",[64],"NA","Purpose To investigate the ability of 18F-FDG PET\u002FCT imaging to detect metastases not detected by conventional imaging (CT and bone scintigraphy) in patients diagnosed with stage II\u002FIII and locoregional recurrent breast cancer (BC) which can affect the choice of treatment.\n\nHypothesis The hypothesis is that 18F-FDG PET\u002FCT can provide information about disease stage beyond the currently used conventional imaging (CT and bone scintigraphy) in patients diagnosed with stage II\u002FIII or locoregional recurrent BC.\n\nObjectives\n\nPrimary:\n\nTo evaluate if a 18F-FDG PET\u002FCT scan in the initial work up of patients diagnosed with stage II\u002FIII or locoregional recurrent BC will lead to change in staging and\u002For treatment.\n\nSecondary:\n\n* Overall survival (OS) and progression-free survival (PFS) in the patients with upstaging based on findings on 18F-FDG PET\u002FCT scan compared with the patients with unchanged stage of disease following 18F-FDG PET\u002FCT.\n* Obtain size of the primary BC from CT\u002FMRI scan and evaluate if these metrics are correlated to outcome.\n* Obtain PET parameters from the primary BC: maximum, mean, and peak standardized uptake value (SUVmax, SUVmean, SUVpeak), metabolic tumour volume (MTV), total lesion glycolysis (TLG), total MTV and total TLG and evaluate if these metrics are correlated with outcome.\n* Obtain CT and PET texture parameters from the primary BC and evaluate if these metrics are correlated with outcome.\n* Blood and tumor samples for molecular characterisation:",[67,68],"Breast Cancer Female","Breast Cancer Recurrent","2024-05-08",{"date":71,"type":72},"2024-05-09","ACTUAL",{"date":74,"type":72},"2023-02-16",{"date":76,"type":61},"2032-12-31",{"name":5,"class":6},1]